Allergan Articles
Spectrum regains rights from Allergan for apaziquone
3 February 2013
Allergan to acquire MAP Pharmaceuticals in $958 million deal
24 January 2013
Regulatory briefs from GSK/Theravance, Allergan and Mylan
19 December 2012
Allergan to acquire SkinMedica business for $350 million
18 November 2012
Migraine drug sales to grow to $5.8 billion in 2021 in major markets
18 November 2012
Allergan 4th-qtr revenues up 6%; earnings exceed expectations
31 October 2012
Watson gets FDA approval for generic Sanctura XR and Avapro
14 October 2012
Allergan's1 st-qtr profits leap 45%
3 May 2012
FDA delay for MAP Pharma migraine drug candidate
28 March 2012
UK NICE asks for more data on Tarceva, and Botox for migraine
17 February 2012
Regeneron and Bayer’s Eylea backed by thought leaders for DME
13 February 2012
2011 financial briefs for Alkermes, Allergan, Gilead and Vertex
3 February 2012
Good news for RVO suffers as EU approves Novartis’ Lucentis and NICE backs Allergan’s Ozurdex
6 June 2011
Allergan and MAP Pharma collaborate on Levadex for acute migraine, in deal worth potential $157 million
2 February 2011
US FDA approves Bayer’s Beyaz, a combination contraceptive with folate, and Allergan’s Ozurdex
26 September 2010
Watson confirms US patent challenge to Allergan’s eye drug Combigan
8 September 2010
Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
2 September 2010
Approval of Allergan’s Botox for migraine “a headache for regulators and payers,” says Datamonitor
30 July 2010
Allergan sells Bristol-Myers Squibb rights to early-stage pain drug for up to $413 million
4 March 2010
Spectrum and Nippon Kayaku in deal for apaziquone in Asian territories worth as much as $151 million
11 November 2009
Allergan wins in Brimonidine patent infringement case
26 October 2009
Allergan takes legal action against US govt over right to share info with physicians on Botox
5 October 2009
FDA asks for more info on new Botox indication
28 May 2009
URCH study foresees more pharma mega-mergers
27 April 2009
Stock Commentary - Europe - week to mar 30, 2009
2 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
GSK news includes Allergan buy rumors
30 March 2009
Stock Commentary - New York week to Mar 16, 2009
23 March 2009
ExonHit gears up for "pivotal year"
16 March 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
PDCO refuses PIPs for Lilly, Allergan, Neurim and AZ
23 February 2009
Allergan's 4th-qtr profit falls 6% on 3% sales drop
16 February 2009
Allergan's eyelash enhancer gets FDA approval
12 January 2009
ExonHit and Allergan extend R&D accord
12 January 2009
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
FDA panel backs Allergan's Latisse
15 December 2008
Allergan may be facing cloud with silver-lining
10 November 2008
Allergan licenses Polyphor's PEM drugs in $61M deal
10 November 2008
Allergan/Spectrum in $345M apaziquone deal
10 November 2008
Botox sBLA to be filed for chronic migraine
22 September 2008
Asterand gets $6M+ Allergan milestone
15 September 2008
Indevus makes $105M placing
1 September 2008
QLT closes Aczone deal with Allergan
21 July 2008
FDA clears Allergan's Trivaris
23 June 2008
Allergan acquires QLT acne treatment
16 June 2008
Stock Commentary - New York week to June 2, 2008
9 June 2008
Allergan's Ganfort beats Xalacom in trial
9 June 2008
Allergan gets Canadian right to Sanctura
2 June 2008
FDA accepts Reloxin BLA, Ipsen gets $25M
26 May 2008
Ipsen/Medicis submit Reloxin BLA to FDA
24 March 2008
ExonHit 2007 loss up 56% on higher costs
17 March 2008
Allergan gets subpoena for Botox promotion
10 March 2008
US FDA opens safety review on Botox
18 February 2008
Allergan's 4th-qtr 17% sales hike still short
14 February 2008
Allergan's 3rd-qtr 2007 net income jumps 50%
19 November 2007
Allergan gains FDA appro for Combigan
12 November 2007
Allergan buys Esprit Pharma for $370M in cash
27 September 2007
ExonHit and Allergan's R&D accord yields drug candidate
3 September 2007
Allergan's income soars 86% in 2nd-qtr
13 August 2007
Stock Commentary - New York week to August 6, 2007
13 August 2007
Acadia earns milestone on glaucoma candidate
23 July 2007
Combigen gets FDA approvable letter
8 January 2007
EHT 0202 upregulates production of beneficial peptide in AD
4 December 2006
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Allergan buys Groupe Corneal for $217M
13 November 2006
Freedonia predicts 7% per year rise in US enzyme demand to 2010
30 October 2006
CORRECTION: Joe Papa appointment
23 October 2006
Allergan launches to Juvederm products
2 October 2006
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
